Alprazolam-ritonavir interaction: implications for product labeling.

@article{Greenblatt2000AlprazolamritonavirII,
  title={Alprazolam-ritonavir interaction: implications for product labeling.},
  author={David J Greenblatt and Lisa L. von Moltke and Jerold S. Harmatz and A. L. B. Durol and Johanna Daily and Jennifer A. Graf and Polyxane Mertzanis and James L. Hoffman and Richard I. Shader},
  journal={Clinical pharmacology and therapeutics},
  year={2000},
  volume={67 4},
  pages={335-41}
}
BACKGROUND Pharmacokinetic interactions involving antiretroviral therapies may critically influence the efficacy and toxicity of these drugs, as well as pharmacologic treatments of coincident or complicating diseases. The viral protease inhibitor ritonavir is of particular concern since it both inhibits and induces the activity of cytochrome P450 3A (CYP3A… CONTINUE READING